Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)

Video
Conferences|ASRS

Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

Daniel F. Kiernan, MD, FACS, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation, "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery," during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

See more ASRS meeting coverage here

Recent Videos
Related Content
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Article
Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management: Expert Insights into Innovative Approaches

Podcast
Richard Rosen, MD, honored with distinguished award from ASRS

Richard Rosen, MD, honored with distinguished award from ASRS

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
ASRS 2024: TEASE-3 study data shows progression stalled in early-stage Stargardt disease patients treated with gildeuretinol

ASRS 2024: TEASE-3 study data shows progression stalled in early-stage Stargardt disease patients treated with gildeuretinol

Article
ASRS 2024: Retina surgeon dexterity affected by external exposures

ASRS 2024: Retina surgeon dexterity affected by external exposures

Article
© 2024 MJH Life Sciences

All rights reserved.